Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 13/20 | 0.46 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491499 | 0.87 | SYK (0.51) | SYKEGFRCNR2KDRSCN9A | |
| SCHEMBL6488921 | 0.86 | AURKA (0.53) | SYKEGFRCNR2KDRSCN9A | |
| SCHEMBL6480431 | 0.85 | SYK (0.54) | SYKSCN9ACCNT1CCNE1CDK2 | |
| SCHEMBL14214606 | 0.79 | KDR (0.47) | EGFRCNR2KDRSCN9ACDK2 | |
| SCHEMBL4547562 | 0.79 | SYK (0.53) | SYKMAPT | |
| SCHEMBL12154943 | 0.79 | SYK (0.53) | SYKMAPT | |
| SCHEMBL136054 | 0.78 | SLC7A5 (0.55) | EGFRMAPT | |
| SCHEMBL29700723 | 0.78 | SLC7A5 (0.55) | EGFRMAPT | |
| SCHEMBL6492733 | 0.75 | PIK3CA (0.50) | SYKKDRSCN9A | |
| SCHEMBL7338826 | 0.74 | SLC7A5 (0.58) | SYKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1390354-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | Amgen Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2002083653-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | SYK 593/4885EGFR 228/4885ERBB3 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.